Evidence map›Paper›PMID 42966964›Full record

ReviewMedComm2026

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies.

Yibing Zhang, Siwen Wu, Yusi Wang, Die Hu, Li Yang

Abstract readReview
In one paragraph

Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yibing ZhangDepartment of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu China.
Siwen WuDepartment of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu China.
Yusi WangDepartment of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu China.
Die HuDepartment of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu China.
Li YangDepartment of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophils are the most abundant circulating leukocytes and are essential components of innate immunity, contributing to host defense, inflammation, tissue remodeling, and disease progression. Increasing evidence has revealed substantial neutrophil heterogeneity and functional plasticity, which enable distinct neutrophil populations to exert protective or pathogenic effects depending on the tissue and disease context. These properties have attracted growing interest in neutrophils as therapeutic targets and as vehicles for targeted drug delivery. This review summarizes the biological characteristics and functional heterogeneity of neutrophils, with particular emphasis on their recruitment, phagocytosis, oxidative responses, extracellular trap formation, and interactions with the tissue microenvironment. We further discuss the diverse roles of neutrophils in cancer, inflammatory diseases, infectious diseases, and other pathological conditions, highlighting their context-dependent functions. Building on these insights, we review current and emerging therapeutic strategies, ranging from broad neutrophil modulation to precision targeting and neutrophil-based drug delivery. Living neutrophil carriers, neutrophil membrane-coated nanoparticles, and neutrophil-derived vesicles are comparatively evaluated in terms of preparation, cargo loading, targeting properties, advantages, limitations, and translational potential. Finally, we discuss key challenges in the development and clinical translation of neutrophil-based therapies, including manufacturing, quality control, safety, and therapeutic precision, and highlight future opportunities for their clinical application.

Indexed as

heterogeneityneutrophil‐based delivery systemsneutrophilsneutrophil‐targeted therapyprecision drug delivery

Identifiers

PMID42966964
PMCPMC13722946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.